ACE Inhibitors and ARBs - Renal and Potassium Principles

Key Points

• A modest creatinine rise after ACEI/ARB initiation can reflect expected hemodynamic change rather than kidney injury.
• Check creatinine and potassium after starting or increasing therapy.
• Investigate a large or progressive creatinine rise for volume, NSAIDs, diuretics, renal artery disease, or obstruction.
• CKD, diabetes, potassium-sparing drugs, trimethoprim, and supplements increase hyperkalemia risk.
• Do not routinely combine an ACE inhibitor with an ARB.
• Temporary holding during severe acute illness should be followed by an explicit restart review.
• ACE-inhibitor angioedema is an airway emergency.
• ACE inhibitors/ARBs are contraindicated in pregnancy.

Algorithm

1. Confirm indication and obtain baseline BP, creatinine/eGFR, potassium, and medication list.
2. Start at an appropriate dose and recheck renal function/potassium after initiation or titration.
3. If creatinine rises modestly and stabilizes, continue while monitoring.
4. For larger rises, evaluate volume status, NSAIDs, diuretics, obstruction, and renovascular disease.
5. For hyperkalemia, remove contributors and use potassium-lowering strategies when appropriate.
6. Hold during shock/severe dehydration or rapidly progressive AKI.
7. Restart after acute illness when the long-term indication remains and labs permit.
8. Stop permanently and provide emergency care for ACE-inhibitor angioedema.

Clinical Synopsis & Reasoning

ACE inhibitors and ARBs dilate the efferent arteriole, lowering intraglomerular pressure. This is part of why they protect proteinuric kidneys over time but also why serum creatinine often rises after initiation. A modest rise, often up to roughly 30% from baseline in a stable patient, can be acceptable if potassium and volume status are safe. A larger or progressive increase requires evaluation rather than assuming the drug is directly nephrotoxic.

Hyperkalemia risk is greatest in CKD, diabetes, older age, dehydration, and combination with potassium supplements, potassium-sparing diuretics, trimethoprim, NSAIDs, or other RAAS blockers. ACE inhibitors and ARBs should not routinely be combined because dual blockade adds AKI and hyperkalemia without sufficient benefit in most settings.

These agents are core therapy in HFrEF and albuminuric CKD and are common first-line antihypertensives. Their long-term benefit can be lost when they are permanently stopped during a temporary AKI and never restarted. Conversely, continuing them through shock, severe volume depletion, or rapidly progressive AKI can worsen hemodynamic kidney dysfunction. The decision should follow the patient's current physiology.

ACE inhibitors can cause cough and rare but life-threatening angioedema. ARBs have a much lower cough rate and lower but nonzero angioedema risk. Pregnancy is a contraindication because fetal renal injury can occur, especially later in gestation; pregnancy-capable patients need appropriate counseling.

Treatment Strategy & Disposition

Before starting or increasing dose, obtain blood pressure, creatinine/eGFR, potassium, and medication review. Recheck labs after initiation or titration, commonly within 1 to 2 weeks in higher-risk patients and according to local guidance. More rapid monitoring is appropriate with advanced CKD, high baseline potassium, or combined diuretic/mineralocorticoid therapy.

If creatinine rises, evaluate percent change and clinical context. Correct volume depletion, stop unnecessary NSAIDs, review diuretic intensity, and consider renal-artery stenosis when the rise is large, particularly with flash pulmonary edema or asymmetric kidneys. Mild stable elevation alone may not justify stopping a drug that is providing strong heart-failure or kidney benefit.

For hyperkalemia, review supplements, diet, trimethoprim, NSAIDs, potassium-sparing medications, and metabolic acidosis. Modern potassium binders can sometimes allow continuation of disease-modifying RAAS therapy in selected patients rather than permanent discontinuation. Severe hyperkalemia or ECG changes require emergency treatment.

Hold ACEI/ARB temporarily during severe hypotension, shock, significant dehydration, or evolving AKI when continued efferent vasodilation is unsafe, then deliberately reassess for restart after recovery. Angioedema requires immediate discontinuation and airway-focused emergency care.

Epidemiology / Risk Factors

• RAAS blockers are among the most widely used cardiovascular and kidney-protective medications.
• Hyperkalemia and creatinine rise are common reasons for discontinuation, sometimes unnecessarily.
• Patients with CKD and HFrEF derive substantial long-term benefit when therapy can be maintained.
• Pregnancy-related exposure remains a preventable medication-safety concern.

Investigations

Hold When

Pharmacology

Prognosis / Complications

• Appropriate use reduces cardiovascular events, heart-failure hospitalization, and progression of albuminuric CKD.
• Most modest hemodynamic creatinine increases stabilize.
• Severe hyperkalemia or unrecognized bilateral renal-artery disease can cause significant harm.
• Deliberate restart after temporary AKI can preserve long-term benefit.

Patient Education / Counseling

• Do not use potassium supplements or salt substitutes without checking with the care team.
• Avoid frequent NSAID use unless specifically approved.
• Have kidney and potassium tests drawn after dose changes.
• Seek emergency help for lip/tongue swelling, trouble breathing, fainting, or severe weakness/palpitations.
• Tell the clinician immediately about pregnancy or pregnancy plans.

Notes

The creatinine rise after RAAS blockade is a hemodynamic signal, not automatically structural nephrotoxicity. The clinical error can occur in either direction: ignoring a dangerous large rise or permanently stopping a beneficial drug for an expected modest change.

Acute-care medication lists should include a restart plan. 'Held during AKI' is incomplete documentation if the patient still has HFrEF or albuminuric CKD and no one is assigned to reassess the drug after recovery.

References

1. KDIGO Clinical Practice Guidelines — Link
2. 2025 ACC/AHA Guideline for High Blood Pressure — Link